The National Advisory Committee on Immunization (NACI) recommends that SHINGRIX should be offered to adults 50 years of age and older (strong recommendation).1
According to NACI, a strong recommendation applies to most individuals and should be followed unless a clear and compelling rationale for an alternative approach is present.1
Refer to the NACI statement on the Public Health Agency website for further information.
© All rights reserved. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccine. Public Health Agency of Canada modified: 2018. Adapted and reproduced with permission from the Minister of Health, 2018.